Business Wire

CA-VELO3D

24.8.2021 15:34:09 CEST | Business Wire | Press release

Share
Velo3D Expands Team in Europe to Support Growing Demand for Industrial Metal Additive Manufacturing

As global demand for top-quality 3D-printed industrial parts continues to grow, California-based Velo3D, Inc. , a leader in advanced additive manufacturing (AM) for high-value metal parts, has announced the appointment of two new Europe-based senior executives.

Managing Director, Dr. Jose Greses , will be based between Germany and Spain while Sales Director, Xavier Fruh , will be located in France. They join Jon Porter , who was appointed earlier this year as European Business Development Director based in the U.K.

Dr. Greses holds a Ph.D. in laser welding from the University of Cambridge (U.K.) and a M.Sc. in Marine Technology from Cranfield University (U.K.). He has worked for a number of leading European manufacturing companies in laser welding and 3D-printing—most recently with GF Machining Solutions and, prior to that, for 14 years with German AM company EOS.

"Our goal is to help industries solve their engineering challenges by delivering unprecedented design freedom, part repeatability and quality in metal 3D printing," says Dr. Greses. "We're here to provide the European markets with a seamless transition to Velo3D's end-to-end manufacturing solution including its advanced support-free technology."

Xavier Fruh has a Master's degree in electrical engineering from ESIGELEC Rouen and an M.B.A. from the Strasbourg School of Management, both in France. He has years of experience in the welding industry and most recently did business development around Europe for four years with AddUp, a French group specializing in AM technology.

"I am passionate about innovation and technology," Fruh says. "I'm keen to support our customers in overcoming the limits of traditional manufacturing and to help them take advantage of everything that AM, the next generation of manufacturing engineering, has to offer."

Benny Buller , founder and CEO of Velo3D, views his company's European growth as a sign of greater awareness of the production metrics delivered by advanced 3D-printing systems. "Expanding our footprint in Europe comes in response to new demand for the very highest-achievable levels of metal AM quality that only Velo3D provides--as well as design freedom that can unleash innovation and improve competitiveness for industries such as aerospace, oil and gas, and alternative energy," he says.

In March, Velo3D announced plans to merge with JAWS Spitfire Acquisition Corporation (NYSE: SPFR ) and become a public company.

To learn more about how Velo3D empowers engineers and designers to imagine more and additively manufacture nearly anything, follow Velo3D on LinkedIn or visit velo3d.com .

About Velo3D

Velo3D, one of Fast Company’s 2021 World’s Most Innovative Companies , empowers engineers and designers to imagine more and additively manufacture nearly anything with a fully-integrated patented solution of software, hardware, and process-control featuring FlowTM print preparation software, AssureTM quality assurance software and the Sapphire® family of laser powder bed 3D printers. Velo3D additive manufacturing solutions for 3D-printing high-value metal parts allow for previously impossible geometries, so businesses can make the mission-critical parts they need without compromise. Customers include some of the world’s most visionary companies, such as Aerojet Rocketdyne, Chromalloy, Honeywell, LAM Research and Raytheon Technologies. For more information, follow Velo3D on LinkedIn or visit velo3d.com.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release

The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye